4P-Pharma, a Lille, France-based clinical-stage biotechnology company, raised 15M in Second funding.
Backers were not disclosed.
The company intends to use the funds to deploy its drug regeneration model and to engage actively external growth opportunities through M&A and licensing-in and accelerate its startup studio model for building a balanced pipeline towards the commercial stage.
Founded in 2014 and led by CEO Revital Rattenbach, 4P-Pharma is a clinical-stage biotechnology company dedicated to developing innovative curative therapies for severe diseases with unmet medical needs. Its goal is to bring first-class medicines to patients rapidly. 4P-Pharma leverages drug candidates with reduced development times, partly thanks to regulatory opportunities (emergency use or conditional market authorization) with strong intellectual property.
Commenting on the news, Revital Rattenbach said: “As CEO of 4P-Pharma, I am pleased with the renewed trust of our investors placed in our scientific and development approach year after year. This financial endorsement underscores our significant progress over the past decade. It attests to the strength of our model for delivering first-in-class treatments for people suffering from untreated serious diseases.”
The company is headquartered in Lille and Paris and has over 20 employees.
FinSMEs
29/04/2024